PloS one, 2012-08, Vol.7 (8), p.e41401
2012
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma
- Ist Teil von
- PloS one, 2012-08, Vol.7 (8), p.e41401
- Ort / Verlag
- United States: Public Library of Science
- Erscheinungsjahr
- 2012
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- Recently, there has been renewed interest in the role of tumor stem cells (TSCs) in tumorigenesis, chemoresistance, and relapse of malignant tumors including osteosarcoma. The potential exists to improve osteosarcoma treatment through characterization of TSCs and identification of therapeutic targets. Using transcriptome, proteome, immunophenotyping for cell-surface markers, and bioinformatic analyses, heterogeneous expression of previously reported TSC or osteosarcoma markers, such as CD133, nestin, POU5F1 (OCT3/4), NANOG, SOX2, and aldehyde dehydrogenase, among others, was observed in vitro. However, consistently significantly lower CD326, CD24, CD44, and higher ABCG2 expression in TSC-enriched as compared with un-enriched osteosarcoma cultures was observed. In addition, consistently higher CBX3 expression in TSC-enriched osteosarcoma cultures was identified. ABCA5 was identified as a putative biomarker of TSCs and/or osteosarcoma. Lastly, in a high-throughput screen we identified epigenetic (5-azacytidine), anti-microtubule (vincristine), and anti-telomerase (3,11-difluoro-6,8,13-trimethyl- 8H-quino [4,3,2-kl] acridinium methosulfate; RHPS4)-targeted therapeutic agents as candidates for TSC ablation in osteosarcoma.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1932-6203eISSN: 1932-6203DOI: 10.1371/journal.pone.0041401Titel-ID: cdi_plos_journals_1326222357
- Format
- –
- Schlagworte
- Adolescent, Aldehyde dehydrogenase, Antineoplastic Combined Chemotherapy Protocols - pharmacology, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, ATP-Binding Cassette Transporters - biosynthesis, Azacitidine - pharmacology, Azacitidine - therapeutic use, Azacytidine, Biocompatibility, Biology, Biomarkers, Biomarkers, Tumor - biosynthesis, Biomedical materials, Bone cancer, Breast cancer, Cancer therapies, CD44 antigen, Cell Line, Tumor, Cell surface, Chemical compounds, Chemoresistance, Chemotherapy, Chromosomal Proteins, Non-Histone - biosynthesis, Colon, Comparative analysis, Dehydrogenases, Enrichment, Epigenetic inheritance, Femoral Neoplasms - drug therapy, Femoral Neoplasms - metabolism, Femoral Neoplasms - pathology, Gene expression, Gene Expression Regulation, Neoplastic, Genetic aspects, Genomics, Growth factors, Health aspects, Humans, Identification, Male, Medicine, Melanoma, Metabolism, Metastasis, Neoplasm Proteins - biosynthesis, Neoplastic Stem Cells - metabolism, Neoplastic Stem Cells - pathology, Nestin, Oct-4 protein, Osteosarcoma, Osteosarcoma - drug therapy, Osteosarcoma - metabolism, Osteosarcoma - pathology, Pharmacology, Prostate, Proteomes, Sarcoma, Skin cancer, Spheres, Stem cells, Surface markers, Target recognition, Telomerase, Therapeutic applications, Tumorigenesis, Tumors, Vincristine, Vincristine - pharmacology, Vincristine - therapeutic use